Virtual Library

Start Your Search

H. Kim



Author of

  • +

    P1.02 - Biology/Pathology (ID 614)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Biology/Pathology
    • Presentations: 1
    • +

      P1.02-003 - Prevention of Adriamycin-induced Cardiac Damage by NAD-ModulationPrevention of Adriamycin-induced Cardiac Damage by NAD-Modulation (ID 9137)

      09:30 - 16:00  |  Author(s): H. Kim

      • Abstract
      • Slides

      Background:
      Adriamycin (ADR), a potent anticancer chemotherapeutic agent, is used to treat a variety of human neoplasms. However, its clinical use is hampered by severe side effects including cardiotoxicity. It has been reported that ADR-induced cardiotoxicity is related to myocardial oxidative stress, disruption of cellular and mitochondrial Ca[2+] homeostasis and DNA damage. Nevertheless, the remedy for ADR cardiotoxicity is still not developed. Here we describe the effect of NAD[+]/NADH modulation by NQO1 enzymatic action on ADR-induced cardiotoxicity in mice.

      Method:
      C57BL/6 male mice were intraperitoneally injected with ADR. Before and after exposure to ADR, the mice were orally administrated with WK0202, a substrate of NQO1, (20 mg/kg body weight of mice). Cardiac biomarkers (CPK, Trop I, LDH and SGOT) in plasma levels, oxidative biomarkers and mRNA levels of pro-inflammatory cytokines were determined to compare cardiac toxicity of each experimental group.C57BL/6 male mice were intraperitoneally injected with ADR. Before and after exposure to ADR, the mice were orally administrated with WK0202, a substrate of NQO1, (20 mg/kg body weight of mice). Cardiac biomarkers (CPK, Trop I, LDH and SGOT) in plasma levels, oxidative biomarkers and mRNA levels of pro-inflammatory cytokines were determined to compare cardiac toxicity of each experimental group.

      Result:
      Cardiac biomarkers in sera, oxidative biomarkers, and mRNA levels of pro-inflammatory cytokines were significantly increased in ADR-treated mice. However, these increases were significantly alleviated by WK0202. We also demonstrated that the downfall in SIRT1 and SIRT3 activities is critically involved in ADR-induced cardiotoxicity through acetylation of NF-κB p65 and p53. However, increase of NAD[+]/NADH by WK0202 through NQO1 enzymatic action attenuated ADR-induced cardiotoxicity through recovery of SIRT1 and SIRT3 activities and subsequent deacetylation of NF-κB p65 and p53. .

      Conclusion:
      WK0202 has a protective effect against ADR-induced acute cardiotoxicity through NQO1 enzymatic action. Therefore, WK0202 might be a new therapeutic option for preventing chemotherapy-associated side effects.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.